November 04, 2015

Increased Funding of Research Awards Announced

Research awards will increase from $25,000 to $35,000 each

Over the course of 12 years and $1 million in research awards, the Respiratory Disease Research Board (formerly the PRRS Research Review Board), with financial support from Boehringer Ingelheim Vetmedica, Inc. (BIVI), has helped fund research answering some of producers’ most pressing questions about porcine reproductive and respiratory disease (PRRS). Beginning with awards granted in 2016, the board and BIVI will build on that success by increasing the amount of funding by $10,000 per award.

In 2016, the board will begin awarding three (3) $35,000 awards for research seeking to better understand the control and management of PRRS and other swine respiratory diseases. This 40 percent increase is intended to strengthen the industry’s response to the constant challenge of managing swine respiratory diseases, according to board members.

“As the swine industry continues to change, it is imperative that resources are available for researchers looking to find answers to production questions,” says Dr. Montse Torremorell, University of Minnesota researcher and member of the Respiratory Disease Research Board. “The decision to increase Research Award funding demonstrates our commitment to meeting the industry’s need for high-quality swine respiratory disease research.”

Practicing veterinarians and researchers seeking an Award for Advancing Research in Respiratory Disease (formerly PRRS Research Award) need to submit a proposal by January 1, 2016. Additional instructions and submission forms are available at under ‘Download Forms.’ Also new in 2016, proposals for research in the areas of porcine circovirus Type 2 (PCV2), Mycoplasma hyopneumoniae and influenza A virus in swine (IAV-S) — in addition to PRRS — are eligible for funding.

Historically the Research Award program has impacted the industry through research projects that delivered additional diagnostic testing and sampling processes, identified more effective biosecurity practices, sought to understand virus transmission and developed risk assessment tools, therapeutic intervention programs and vaccination strategies. The program is supported through funding from Boehringer Ingelheim Vetmedica, Inc. (BIVI).

“PRRS and other swine respiratory diseases are high-risk, potentially very costly, challenges that swine producers must be able to manage,” says Dr. Reid Philips, technical manager, BIVI. “It is only appropriate that the Research Review Board, supported by BIVI, boosts the level of support provided to researchers developing stronger responses to these diseases. More than 12 years of successful Research Review Board programs give BIVI confidence that supporting increased Research Awards is a good investment.”

For more information on the Respiratory Disease Research Board and the Research Award program, visit

About the Respiratory Disease Research Board

The Respiratory Disease Research Board, an independent group of swine veterinarians and researchers, selects the Awards for Advancing Research in Respiratory Disease annually. Board members for the 2016 award selection process include:

  • Luc Dufresne, DVM, Seaboard Foods, Shawnee Mission, Kansas
  • Tim Loula, DVM, Swine Vet Center, P.A., St. Peter, Minnesota
  • Daryl Olsen, DVM, AMVC, Audubon, Iowa
  • Montse Torremorell, DVM, Ph.D., University of Minnesota, St. Paul
  • Bill Mengeling, DVM, Ph.D., Diplo. ACVM, Iowa State University, Ames (Retired)
  • AASV President
  • AASV Young Swine Veterinarian of the Year

About Boehringer Ingelheim Vetmedica, Inc.

Boehringer Ingelheim Vetmedica, Inc. (BIVI) is the fifth-largest animal health company in the United States and produces innovative vaccine and pharmaceutical products for the prevention and treatment of diseases in the swine, cattle, equine and companion animal markets. BIVI is the U.S. subsidiary of the global Boehringer Ingelheim Animal Health GmbH. Our U.S. headquarters are located within the KC Animal Health Corridor in St. Joseph, Mo., with other locations in Ames, Fort Dodge and Sioux Center, Iowa.

With more than 3,600 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about 1.13 billion euros in 2014. In our research-driven Animal Health business, Boehringer Ingelheim continually invests more than 11 percent of net sales of the Animal Health business in R&D.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.